Dysfunction of respiratory system in patients with diabetes mellitus and coronary artery disease

Aims: we aimed to estimate the main parameters characterizing respiratory pulmonary function in patients with isolated type 2 diabetes mellitus (T2DM) and coronary artery disease (CAD), as well as with their combination.

Materials and methods: the study included 198 patients divided into 3 groups: I – with isolated CAD [94 (47.5%)], II – with T2DM without the signs of CAD [64 (32.3%)], III – with combined CAD and T2DM [40 (20.2%)]. The assessment of carbohydrate and lipid metabolism, as well as the measurement of inflammatory markers were performed using unified clinical and biochemical methods. Respiratory pulmonary function and diffusion lung capacity (Dlco) were assessed using Elite Dl-220v body plethysmograph.

Results: the parameters reflecting the respiratory pulmonary function and the level of gas diffusion through alveolar-capillary membrane (ACM) in patients with CAD both with and without diabetes was within the normal values. The exception was the level of residual volume, which was below the prognostic values in all the studied groups. At the same time, in diabetic patients with CAD the values of forced and slow vital lung capacity, forced expiratory volume for 1-second, as well as the level of diffusion were significantly lower as compared to the corresponding values in patients with isolated CAD and didn’t differ in comparison with the values of diabetic patients except for the level of diffusion. It should be noted that a number of respiratory parameters had a correlation relationships with glycemic level, inflammatory markers and with the indicators characterizing dyslipidemia and myocardial dysfunction.

Conclusions: in the course of the study it was found out that the diabetic patients had respiratory system dysfunction in comparison to the patients with isolated CAD. The presence of diabetes in patients with CAD worsens not only the somatic background but probably contributes to the respiratory dysfunction in the form of lower velocity and volumetric parameters, but also in the indicator showing respiratory metabolism.

diabetes mellitus, coronary artery disease, respiratory dysfunction, pulmonary function

1. Hryhoriy K. Peculiarities of heart rate in the patients with unstable angina and non-ST elevation myocardial infarction and concomitant diabetes mellitus type 2. Wiad Lek. 2016;69(3 pt 2):524-526.

2. Du Y, Chen J, Chen MH. Relationship of lipid and lipoprotein ratios with coronary severity in patients with new on-set coronary artery disease complicated with type 2 diabetics. J Geriatr Cardiol. 2016;13(8):685-692. doi: 10.11909/j.issn.1671-5411.2016.08.007

3. Гайфулин Р.А., Сумин А.Н., Иванов С.В., Барбараш Л.С. Выживаемость после хирургического лечения больных с мультифокальным атеросклерозом в различных возрастных группах // Комплексные проблемы сердечно-сосудистых заболеваний. – 2017. – №2. – C. 6-18. [Gajfulin RA, Sumin AN, Ivanov SV, Barbarash LS. Survival after surgical treatment of multifocal atherosclerosis in different age groups. Complex Issues of Cardiovascular Diseases. 2017;(2):6-18. (In Russ.)] doi: 10.17802/2306-1278-2017-2-6-18

4. Голухова Е.З., Мустафаева А.З. Влияние сахарного диабета II типа на диастолическую функцию миокарда левого желудочка у больных с ишемической болезнью сердца // Креативная кардиология. – 2013. – № 2. – С. 46-52. [Golukhova EZ, Mustafaeva AZ. Effect of type 2 diabetes on left ventricular diastolic function in patients with coronary artery disease. Creative Cardiology. 2013;(2):46-52. (In Russ.)]

5. Rahmani S, Nakanishi R, Budoff MJ. Imaging Atherosclerosis in Diabetes: Current State. Curr Diab Rep. 2016;16(11):105. doi: 10.1007/s11892-016-0799-2

6. Bosevski M, Bosevska G, Stojanovska L. CRP and fibrinogen imply clinical outcome of patients with Type-2 diabetes and coronary artery disease. Acta Biochim Biophys Sin (Shanghai). 2017;49(3):284–285. doi: 10.1093/abbs/gmw135

7. Anandhalakshmi S, Manikandan S, Ganeshkumar S, Ramachandran C. Alveolar gas exchange and pulmonary functions in patients with type II diabetes mellitus. J Clin Diagn Res. 2013;7(9):1874-1877. doi: 10.7860/JCDR/2013/6550.3339

8. Shah SH, Sonawane P, Nahar P, et al. Pulmonary function tests in type 2 diabetes mellitus and their association with glycemic control and duration of the disease. Lung India. 2013;30(2):108–112. doi: 10.4103/0970-2113.110417

9. Vargas HA, Rondon M, Dennis R. Pharmacological treatment and impairment of pulmonary function in patients with type 2 diabetes: a cross-sectional. Biomedica. 2016;36(2):276–284. doi: 10.7705/biomedica.v36i3.2752

10. Sonoda N, Morimoto A, Tatsumi Y, et al. A prospective study of the impact of diabetes mellitus on restrictive and obstructive lung function impairment: the Saku study. Metabolism. 2018;(82):58-64. doi: 10.1016/j.metabol.2017.12.006

11. Лака Г.П., Сакович О.М., Терещенко Ю.А. Вовлекаются ли легкие в патологический процесс при сахарном диабете? // Сибирское медицинское обозрение. – 2010. – №2. – С. 9–16. [Laka GP, Sakovich OM, Tereschenko YuA. Are lungs involved into pathological process at diabetes? Siberian Medical Review. 2010;(2):9-16. (In Russ.)]

12. Fuso L, Pitocco D, Longobardi A, et al. Reduced respiratory muscle strength and endurance in type 2 diabetes mellitus. Diabetes Metab Res Rev. 2012;28(4):370–375. doi: 10.1002/dmrr.2284

13. Araz M, Bayrac A, Ciftci H. The impact of diabetes on left ventricular diastolic function in patients with arterial hypertension. North Clin Istanb. 2015;2(3):177-181. doi: 10.14744/nci.2015.55477

14. Назаров Б.М., Зыков К.А., Ратова Л.Г., и др. Нужна ли спирометрия при сердечно-сосудистых заболеваниях? // Системная гипертензии. – 2013. – №2. – С. 69–74. [Nazarov BM, Zykov KA, Ratova LG, et al. Do spirometry for patients with cardiovascular diseases? Systemic Hypertension. 2013;(2):69-74. (In Russ.)]

15. Дедов И.И., Шестакова М.В., Майоров А.Ю., и др. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. / Под ред. Дедова И.И., Шестаковой М.В., Майорова А.Ю. 8-й выпуск // Сахарный диабет. — 2017. — Т. 20. — №1S. — C. 1-121. [Dedov II, Shestakova MV, Mayorov AY, et al. Dedov II, Shestakova MV, Mayorov AY, editors. Standards of specialized diabetes care. 8th ed. Diabetes mellitus. 2017;20(1S):1-121. (In Russ.)] doi: 10.14341/DM20171S8

16. Davis TM, Knuiman M, Kendall P, et al. Reduced pulmonary function and its associations in type 2 diabetes: the Fremantle Diabetes Study. Diab Res Clin Pract. 2000;50(2):153–159. doi: 10.1016/S0168-8227(00)00166-2

17. Goldman M. Lung dysfunction in diabetes. Diabetes Care. 2003;26(6):1915–1918. doi: 10.2337/diacare.26.6.1915

18. Guazzi M, Oreglia I, Guazzi MD. Insulin improves the alveolar-capillary membrane gas conductance in Type 2 diabetes mellitus. Diabetes Care. 2002;25(10):1802-1806. doi: 10.2337/diacare.25.10.1802

19. McKeever TM, Weston PJ, Hubbard R, Fogarty A. Lung function and glucose metabolism: an analysis of data from the Third National Health and Nutrition Examination Survey. Am J Epidemiol. 2005;161(6):546–556. doi: 10.1093/aje/kwi076

20. Engström G, Janzon L. Risk of developing diabetes is inversely related to lung function: a population-based cohort study. Diabet Med. 2002;19(2):167–170. doi: 10.1046/j.1464-5491.2002.00652.x

21. Gade J, Qvortrup K, Andersen CB, Olsen PS. Bronchial transsection and reanastomosis in pigs with and without bronchial arterial circulation. Ann Thor Surg. 2001;71(1):332–336. doi: 10.1016/S0003-4975(00)02129-9

22. Wang C, Zhang C, Liu L. Macrophage-derived mir-155-containing exosomes suppress fibroblast proliferation and promote fibroblast inflammation during cardiac injury. Mol Ther. 2017;25(1):192-204. doi: 10.1016/j.ymthe.2016.09.001.

23. Klein BE, Moss SE, Klein R, Cruickshanks KJ. Is peak expiratory flow rate a predictor of complications in diabetes? The Wisconsin Epidemiologic Study of Diabetic Retinopathy. J Diab Complications. 2001;15(6):301–306. doi: 10.1016/S1056-8727(01)00170-2